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1. Introduction 
Appetite regulating peptides, particularly ghrelin and leptin in alcohol dependence are 
significantly related with abnormal glucose tolerance or insulin resistance which contribute to 
Type 2 diabetes mellitus (T2DM) [1-5]. Available evidence consistently indicates that altered 
levels of ghrelin and leptin are linked to overall diabetogentc effects of chronic alcohol 
comsumption, and have important mediating roles in the deteriorated pathophysiology of 
T2DM in alcoholic patients [6]. Moreover, these peptides in the regulation of food seeking 
behavior have a similar mechanism of controlling of alcohol craving behavior [7, 8]. 
Threrefore, alterations of the peptides modulating numerous metabolic processes could 
present an intriguing biological mechanism on the relationship between chronic alcohol 
consumption and risk of T2DM. However, the manner in which the peptides contribute to 
the development or maintenance of T2DM with alcohol dependence is not clear. This review 
describes ghrelin and leptin implicated in the elevated risk of developing T2DM with chronic 
use of alcohol that attributes to the impact of glucose and insulin metabolism. Additionally, 
to identify whether these two peptides are relevant to the increase in the clustering of 
metabolic disturbance and progression of T2DM, the background information on the 
peptides, their role in glucose homeostasis and insulin function in addition to their 
mechanism of action are discussed. This review on the relationship between chronic use of 
alcohol and T2DM may further clarify the role of the peptides and provides an insight into 
the effects of chronic alcohol use in the pathophysiology of T2DM.  
2. Pathophysiology of T2DM 
T2DM, known as “non-insulin-dependent DM,” is a complex, multifactorial metabolic 
disorder. Characteristic features of T2DM include chronic hyperglycemia and declining 
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pancreatic β-cell effectiveness, leading to the absence of a first-phase insulin response to 
nutrient ingestion. Further, slower glucose absorption and higher fasting glucose levels 
occur from factors such as a reduced insulin-mediated glucose uptake in muscle, impaired 
hepatic insulin sensitivity, defective insulin action and/or secretion in liver and a disruption 
of secretary function of adipocytes [9-11]. Glucose levels rise and hyperglycemia develops 
from deteriorated insulin secretion [12]. Mechanistically, the manifestation of T2DM features 
a relative decrease in insulin secretion suggesting that this may be in accordance with a 
decreased β-cell mass failing to compensate for peripheral insulin resistance [13-16]. In the 
last two decades, declining pancreatic β-cell effectiveness has been a criterion for the 
development of hyperglycemia and T2DM; its progressive character also determines the 
course of the disease [17]. Impaired glucose-stimulated insulin secretion, defective β-cell 
gene expression and disrupted mitochondrial ultrastructure is thought to be due to lipid 
accumulation and ‘lipoapoptosis’ is observed in pancreatic β-cells from type 2 diabetic 
animals [18]. This is also supported by reports that chronic, high glucose administration 
generates the combination of hyperglycemia and chronic dislipidemia, termed 
‘glucolipotoxicity,’ driving a vicious cycle by which metabolic abnormalities impair insulin 
secretion, which further aggravates metabolic disturbances in β-cell lines and isolated rat 
islets [19].  
There is mounting evidence that chronically elevated circulating levels of glucose and fatty 
acids, critical characteristics of T2DM, contribute to relentless β-cell function decline, by 
endorsing glucolipotoxicity, which induces endoplasmic reticulum (ER) stress [20, 21], 
oxidative stress [22, 23], mitochondrial dysfunction [23, 24] and islet inflammation [25, 26]. 
Several studies have provided evidence that prolonged exposure to increased 
concentrations of fatty acids is associated with reduction of glucose induced insulin 
secretion [27], impairment of insulin gene expression [28, 29] and induction of β-cells death 
[30, 31]. Importantly, lipoapoptosis only occurs in the presence of concomitant elevation in 
insulin secretion [32, 33]. Thus, hyperglycemia and hyperlipidemia have been postulated to 
conduct to the worsening of insulin secretary capacity and β-cell mass observed in T2DM 
[16]. It is to note, that during feeding, insulin secretion occurs in two phases. An elevation of 
insulin synthesis in pancreatic β-cells following an initial rapid release of insulin (i.e. first 
phase) to nutrient ingestion occurs primarily in response to elevated circulating glucose 
concentrations. The insulin level stimulates glucose uptake into striated muscle tissues 
through glucose transport type 4 (GLUT-4) for utilization as a source of energy and into 
adipose tissues for glycerol synthesis; it also affects liver cells thereby activating glycogen 
formation. Consequently, glucose utilization by these different tissues contributes to a 
decrease in concentrations of glucose in blood. Long term release of insulin occurs in 
response to continuously high glucose concentrations as part of the second phase of insulin 
response. On the other hand, during this period of hypoglycemia there is an altered 
interaction between pancreatic islets and glucagon-producing α cells, causing increased 
plasma glucagon, and residual β-cell function largely preserves the first-line defence against 
hypoglycemia in T2DM [34].  
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3. Interplay between alcohol consumption and T2DM 
Chronic, heavy alcohol consumption, an independent risk factor for T2DM [35-37], disrupts 
glucose homeostasis and is associated with development of insulin resistance [38-40]. 
3.1. Epidemiological evidence 
The association between alcohol consumption and DM was demonstrated early in 1971 by 
Phillips et al. [41]. This study suggested that alcohol with doses of 266 to 513 ml produced 
glucose intolerance and insulin resistance in three of six healthy subjects. Later, this 
relationship was also demonstrated in a cross-sectional health screening survey of 636 
individuals with negative urine glucose, suggesting that alcohol dependence was one of the 
malignant factors in individuals with impaired glucose tolerance diagnosed by performing a 
75-g oral glucose tolerance test (OGTT) [42]. Moreover, alcohol consumption influenced 
fasting plasma glucose levels along with obesity after analysis of 434 pairs of adult female 
nondiabetic twins [43]. These results implied that alcohol might impair fasting and 
postprandial glycemic controls and thus may be a risk factor for T2DM, sharing common 
genetic factors. Indeed, alcohol consumption within the past week appears to be an 
independent risk factor of the development of T2DM after a 10 year, prospective 
population-based study [44]. This significant association was observed only in men and 
remained significant after adjusting for other hazards of T2DM.  
However, there also have been studies with negative or opposite findings explaining the 
relationship between alcohol consumption and the development of T2DM. Alcohol 
consumptions of 5-14.9g/d and more than 15g/d were associated with a decreased relative 
risk of DM in women [45]. In a later study worked on younger women, light to moderate 
drinking (<14.9g/d) was also associated with a lower risk of T2DM compared to lifelong 
abstinence, whereas heavy drinking showed a significantly increased diabetic risk [46]. 
Similarly, moderate amount of alcohol consumption (30.0-49.9 g/d) was associated with 
reduced risk of the development of DM in 41,810 male health professionals [47]. Lowering 
the incidence of T2DM by light to moderate drinking, T2DM was also observed in older 
adults [48]. On the other hand, no effect of alcohol consumption on the development of 
T2DM was reported in large population-based survey [49]. The aforementioned results 
suggest the presence of possible influencing factors, such as gender [44, 50] and amount of 
alcohol consumption [46, 50].  
Regarding drinking patterns, Conigrave et al. [51] found that more frequent drinking is 
more protective against T2DM. A later study [50] also showed that binge drinking for 1-3 
days increased the risk of T2DM compared to non-drinking, while drinking the same 
amount over a week did not increase the risk. Meanwhile, there has been controversy on the 
type of alcoholic beverage and the risk of T2DM. Some studies noted protective effects of 
wine on T2DM than other alcoholic beverages [52]. However, other studies presented no 
significant difference with various alcoholic liquors [48, 51]. In addition, obesity may also 
influence the relationship between alcohol consumption and T2DM. A systematic review of 
studies in Japanese showed that alcohol consumption is a risk factor for DM, whereas 
 Glucose Tolerance 104 
moderate drinking is associated with a reduced diabetic risk in higher body mass index 
(BMI) men in some studies [53]. Although the mediating effects of obesity are supported by 
a positive association between alcohol intake, adiponectin levels and insulin sensitivity [54, 
55], more studies will be needed to confirm this issue.  
To date, 3 meta-analyses were performed in an attempt to draw a possible conclusion. 
Carlson et al. [56] analyzed data from 13 cohorts and suggested a U-shaped relationship 
between the amount of alcohol consumption and risk of T2DM. Moderate drinking, 
corresponding to about 5-30g/d was associated with a reduced risk of DM (relative risk: 
RR=0.72, 95% CI=0.67-0.77) in both men and women. This U-shaped relationship in both 
sexes was also demonstrated in a meta-analysis by Koppes et al. [57] in which lowest risk 
was in alcohol drinkers of 6-48g/d. Drinkers of ≥48g/d showed equal RR to that of 
nondrinkers. In their study, adjustment for confounding factors including diagnostic 
measures of T2DM (self-reported versus tested) and BMI (low- versus high-BMI) was 
performed. Results of a self-reported diagnosis were associated with lower RR than using a 
diagnostic test, whereas BMI did not affect the RR of T2DM. A third meta-analysis of 
Bauliunas et al. [58] additionally identified a deleterious effect of heavy drinking (≥60 g/d for 
men and ≥50g/d for women) in addition to the protective effect of moderate drinking in both 
sexes.  
3.2. Alcohol consumption and risk of T2DM 
Along with the epidemiological data on the relationship between alcohol consumption and 
T2DM, studies exploring underlying mechanisms between them have been performed. Most 
directly, alcohol can induce acute and chronic pancreatitis and result in DM as in T1DM 
[59]. However, there is a growing body of evidence suggesting that the diabetogenic effect 
of alcohol does not seem to be mediated by decreased insulin secretion [41]. The priming 
effect of ethanol-enhanced insulin secretion in pancreatic β-cells might be caused by an early 
defence mechanism used to compensate for alcohol-inhibited basal insulin secretion. In 
contrast, a limited number of studies have reported deleterious effects of alcohol on β-cells 
in which alcohol inhibited insulin secretion [60].  
Excessive heavy alcohol use increases ROS production and may be a mechanism of 
pancreatic β-cells dysfunction in T2DM. The reason is that ROS production is one of the 
earliest events in glucose intolerance through mitochondrial dysfunction and β-cells are 
very sensitive to oxidative stress [61]. Previous studies of alcohol dependence have shown 
that alcohol elevated the level of β-cell apoptosis and increased insulin resistance in the liver 
and skeletal muscle, which is among the earliest detectable alterations in humans with 
T2DM [62]. In addition, the mechanisms by which this occurs are often multifactorial and 
quite complex, involving many cell signaling pathways. A common result of DM is 
hyperglycemia, which in turn contributes to the progression and maintenance of an overall 
oxidative environment [63]. In obesity, oxidative stress is now recognized to be an important 
feature in dysregulation of adipokines and inflammation [64].  
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Among potential mediators of alcohol-induced insulin resistance including acetate, lactate, 
acetaldehyde, free fatty acids and triglycerides, hepatic insulin sensitizing substance (HISS) 
and glutathione need to be considered. Alcohol suppresses the release or action of HISS and 
meal-induced insulin sensitization in rats [65]. Moreover, in animal models, acute alcohol 
administration also reduces glutathione [66] which is important for HISS release [67]. As 
with acute alcohol consumption, hepatic glutathione and HISS seem to be involved. In 
contrast to the acute alcohol effect, chronic ethanol consumption increased hepatic 
glutathione levels and HISS release in cases of moderate dose, whereas decreased 
glutathione and HISS were reported at high doses [68].  
On the other hand, results on the effect of chronic ethanol consumption on insulin 
sensitivity showed that insulin sensitivity was improved [66, 69-72] or unchanged [73-75] 
after chronic alcohol consumption. The mechanism by which chronic alcohol consumption 
enhances insulin sensitivity also remains elusive. Alcohol consumption is proposed to 
increase plasma adiponectin levels, which subsequently lowers plasma TNF-α, which 
interferes with insulin signaling [76]. Taken together, alcohol might induce alterations in 
insulin resistance mediated by lipids, inflammation oxidative stress and altered metabolism. 
Moreover, the effect of alcohol on insulin sensitivity may be influenced by periods of and 
amount of alcohol consumption. Impaired suppression of hepatic glucose production by 
insulin is likely due to impaired insulin signaling in liver after chronic alcohol exposure. For 
instance, chronic ethanol consumption decreases tyrosine phosphorylation of insulin 
receptor substrate-1 as well as activities of PI 3-kinase and Akt (protein kinase B) in the liver 
[77].  
3.3. Ghrelin and leptin correlated with risk of T2DM in alcoholic patients 
It has been investigated that ghrelin may be associated with β-cell hypofunction and the 
first-phase insulin secretion defects in T2DM and exert to regulate glucose homeostasis with 
glucagon and insulin [78]. Additionally, abnormal glucose tolerance and insulin resistance, 
which are main characteristics of T2DM, through performing 75g OGTT seemed to be 
affected by leptin as well as, the levels of leptin were higher in diabetic patients 
independently of body fat mass when it compared with healthy control patients [4]. Thus, 
ghrelin and leptin have been regarded to have influence on T2DM. Valuable efficacy of 
plasma ghrelin and leptin levels by the development of T2DM in patients with alcohol 
dependence were changed [6]. The data showed that ghrelin levels did not differ among the 
groups, even though there was a tendency towards decreased ghrelin levels; whereas the 
leptin level increased significantly with development of T2DM (Fig. 1). 
The demographic characteristics of each group were shown in Table 1. The three groups 
exhibited similar values of age, height, weight, BMI and lipid profiles such as HDL-
cholesterol, LDL-cholesterol, and triglyceride. Fasting glucose concentration and hemoglobin 
A1c, HOMA-IR in the DM group had significantly higher levels than NGT and Pre-DM 
groups. 
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Clinical characteristics NGT Pre-DM DM 
Alcohol history    
Alcohol use disorder identification test 21.7 ± 1.09 21.17 ± 1.61 24.3 ± 1.23 
Alcohol dependency scale 42.29 ± 1.38 38.86 ± 1.74 43.83 ± 1.79 
Onset age of problematic drinking (years) 36.58 ± 1.89 37.56 ± 1.68 40.05 ± 2.88 
General characteristics    
Age (years) 47.35 ± 1.37 48.87 ± 1.57 52.77 ± 1.84 
Weight (kg) 66.83 ± 1.46 65.39 ± 1.25 63.96 ± 1.92 
Height (cm) 169.57 ± 0.81 167.76 ± 0.8 167.38 ± 0.85 
BMI (kg/m2) 23.19 ± 0.42 23.2 ± 0.36 22.77 ± 0.57 
HDL-Cholesterol (mg/dl) 56.91 ± 2.27 51.08 ± 2.36 55.19 ± 4.44 
LDL-Cholesterol (mg/dl) 113.09 ± 3.87 104.63 ± 4.95 101.96 ± 4.72 
Triglyceride (mg/dl) 115.02 ± 10.31 135.33 ± 13.06 139.88 ± 15.54 
GOT (IU/l) 69.5 ± 11.53 71.7 ± 9.19 52.54 ± 6.96 
GPT (IU/l) 40.93 ± 5.25 50.07 ± 8.66 34 ± 6.19 
γ-GTP (IU/l) 178.87 ± 45.33 205.07 ± 32.64 254.96 ± 67.99 
Clinical characteristics related to glucose tolerance    
Fasting Glucose (mg/dl) 86.09 ± 1.05 91.48 ± 1.45 124.19 ± 7.01** 
Fasting Insulin (μU/ml) 4.8 ± 0.84 4.73 ± 0.69 6.22 ± 1.4 
HemoglobinA1c (%Hb A1c) 5.5 ± 0.05 5.64 ± 0.08 7.13 ± 0.36** 
HOMA-IR 1.02 ± 0.17 1.05 ± 0.15 1.87 ± 0.36* 
HOMA-β 83.56 ± 18.56 66.13 ± 11.55 54.91 ± 14.87 
Table 1. Characteristics of subjects classified by oral glucose tolerance test among patients with alcohol 
dependence BMI, body mass index; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-
cholesterol, low density lipoprotein-cholesterol; GOT, glutamate oxaloacetate transaminase; GPT, 
glutamate pyruvate transaminase; γ-GTP, γ-glutamyl transferase; HOMA-IR, homeostasis model 
assessment-insulin resistance; HOMA-β, homeostasis model assessment-β-cell function (*, p<0.05 and 
**, p<0.01 compared with NGT). 
Moreover, this study demonstrated that leptin was significantly correlated with BMI, fasting 
insulin concentration and HOMA-IR reflecting insulin resistance (Table 2). The BMI was 
similar in the groups and the subjects were regarded as a non-obese group. The leptin 
produced by adipocytes increased in proportion to fat mass [79, 80]. The plasma leptin 
levels are highly correlated with BMI in both obese and normal weight subjects [81]. In spite 
of the correlation between BMI and leptin, covarying for BMI in our statistical analyses did 
not alter our findings. 
Leptin also has been shown to be correlated with insulin concentration and insulin 
sensitivity [82-84]. The direct relationship between leptin and insulin seemed to be 
mutual. Insulin also had a role in the regulation of leptin concentrations [85]. Among all 
patients with chronic alcoholism, significant quadratic association of leptin level with 
insulin concentration and HOMA-IR were observed using simple regression analysis (Fig. 2, 
Table 3).  
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Figure 1. Comparison of plasma (a) ghrelin and (b) leptin levels among three groups classified by oral 
glucose tolerance test (OGTT) among alcoholic patients (*, p<0.05 compared with NGT). 
  BMI Insulin Leptin Ghrelin HOMA-IR 
BMI 
Insulin 0.17
Leptin 0.334** 0.379**
Ghrelin -0.066 -0.168 -0.171*
HOMA-IR 0.195* 0.960** 0.388** -0.173  
Table 2. Correlation of BMI, fasting insulin, leptin and ghrelin levels and HOMA-IR (*, p<0.05 and **, p<0.01). 
 
Figure 2. Quadratic regression plots of plasma leptin levels with both insulin resistance index (a) and 
fasting insulin level (b) in chronic alcoholic subjects. The quadratic regression equation was y = 0.007x2 – 
0.037x + 1.075 for fasting leptin level and HOMA-IR (A) and y = 0.031x2 – 0.141x + 4.509 for fasting leptin 
and insulin level (B). 
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Independent-Dependent Linear Quadratic 
Leptin-HOMA-IR 0.390** 0.437** 
Lepin-Insulin 0.363** 0.409** 
Table 3. Comparison of various kinds of regression models to find better model to fit the relationship 
of leptin with HOMA-IR and insulin level (**, p<0.01). 
In conclusion, leptin can play a role in the pathogenesis of T2DM in patients with alcohol 
dependence. Chronic alcohol consumption might produce leptin resistance, which produces 
a significant correlation between leptin and the fasting insulin concentration, β-cell function 
and insulin resistance. However, more study will be needed to determine the mechanism of 
the relationship between alcohol intake and leptin resistance. 
4. Role of the appetite regulating peptides in alcohol dependence and 
prevalence of T2DM 
The neuropeptide, ghrelin secreted from cells of the gastric oxyntic glands in stomach, and 
leptin excreted from white adipose cells, have received attention due their roles in the 
neurobiology of alcohol dependence [2, 6]. Many studies have suggested that ghrelin and 
leptin predominantly produce variations of glucose and insulin concentrations, which may 
initiate metabolic disorders [86, 87]. In addition, recent research regarding 
neuroendocrinological alterations of ghrelin and leptin in patients with alcohol dependence 
has showed that chronic use of alcohol represents a potentially crucial risk factor for T2DM 
prevalence as ghrelin reduces insulin secretion stimulated by the increased level of blood 
glucose in the β cells of pancreas, while in contrast, leptin increases insulin secretion and 
action [88-90]. In regards to the diabetogenic effects of chronic use of alcohol, development 
of pancreatic β-cell dysfunction, insulin resistance, obesity, impairment of liver function in 
glucose metabolism have been noted [35]. Indeed, alcoholic patients with T2DM have 
repeatedly been found to have deregulation of the ghrelin and leptin systems, as indicated 
by impaired insulin secretion, increased hepatic glucose production and decreased 
peripheral glucose utilization [38-40]. Moreover, these peptides are regarded to have an 
influence on T2DM-mediated alcohol cravings and relapses in alcoholism during alcohol 
abstinace [91-94]. Therefore, it is conceivable that alterations of appetite peptides provoked 
by chronic alcohol use might contribute to the development of T2DM, including defective 
glucose tolerance and impaired insulin resistance.  
The decreases in ghrelin are paralleled by increases in leptin and rises in insulin [87, 95]. 
Leptin, which is elevated in the plasma of obese subjects, controls fat cell secretary 
productions on ghrelin secretion due to leptin-related decreases in ghrelin levels. [96-98]. It 
has been suggested that leptin is significantly associated with BMI and alcohol 
consumption, influencing fasting insulin concentration and HOMA-IR, and the passible 
mechamism of alcohol leptin interaction may be attributable to a direct noxious effect of 
alcohol on the pancreatic islet cells, or may reflect a truncal fat pattern related to heavy use 
of alcohol [44]. Thus, the adverse effect of heavy use of alcohol on serum insulin 
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concentrations, a risk for DM, seems to be partially mediated through its effect on BMI. 
Interestingly, it has been proposed that elevated peripheral insulin resistance may produce 
increased leptin concentrations regardless of body fat profiles, suggesting that leptin 
released from fat tissue in alcohol dependence patients may be abundant irrespective of 
body fat content [6]. Therefore, altered leptin concentrations in alcoholic patients contribute 
to the incidence of T2DM mainly due to chronic alcohol consumption rather than body fat 
mass.  
In the clinical studies, increases of mean body weights and leptin concentrations resulted 
from therapeutic treatment of insulin for 1 year in T2DM patients. [99], suggesting that 
insulin prompted leptin secretion, which was believed to exert influence on the increased 
body weight. Further, decrease of insulin-stimulated glucose utilization in skeletal muscle 
was exibited by long periods of leptin exposure. This is to the fact that insulin-stimulated 
p38 mitogen-activated protein kinase (MAPK) activation was inhibited and GLUT4 
activation was decreased by leptin [100]. Leptin also can interfere with insulin signaling and 
induce gluconeogenesis in hepatocytes directly [83]. Insulin-stimulated glucose uptake into 
isolated adipocytes was inhibited by chronic alcohol feeding via vitiation of the fusion of 
GLUT4 vesicles at the plasma membrane of rats. Chronically fed with alcohol sustains 
insulin signaling through PI 3-kinase in adipocytes [101] but results in the disruption of 
insulin mediated Cbl/TC10 signaling pathway which leads to attenuated insulin-stimulated 
glucose transport [102]. Thus, a combination of decreased GLUT4 expression and impaired 
insulin-stimulated GLUT4 trafficking to the plasma membrane contributes to reduced 
glucose uptake in response to insulin in adipocytes. Hence, the possibility that ghrelin and 
leptin can be related with deteriorated pathophysiology of T2DM, aligned with defective 
insulin signaling pathway, including change in kinase activity, glucose transporter 
translocation and intracellular enzyme activity, in alcoholic patients exists. 
5. Ghrelin in glucose and insulin homeostasis 
Ghrelin was originally isolated from the stomach, but ghrelin has also been identified in 
other peripheral tissues, such as the gastrointestinal tract, pancreas, ovary and adrenal 
cortex [3, 103-105]. Regulation of ghrelin secretion, as well as its biological effects, appears to 
be opposite those of leptin and antagonize leptin’s effects in appetite regulation [95, 106-
108]. A suppressive role of ghrelin in insulin secretion from pancreatic islets is supported by 
the observation that ghrelin inhibits glucose-stimulated insulin secretion and disrupts 
glucose tolerance in normal subjects [109]. There is evidence that ghrelin may have 
proliferative or protective roles on β-cells [110] and stimulates insulin secretion, which 
primarily occurs in response to increased circulating glucose levels, whereas insulin reduces 
plasma ghrelin in normal controls and T2DM patients [111]. Moreover, ghrelin may be 
associated with β-cell hypofunction and first-phase insulin secretion defects in T2DM as 
well as regulates glucose homeostasis with glucagon and insulin [78]. Furthermore, it has 
been noted that deficiency of the genes encoding ghrelin and its receptor (GHS-R1a) 
enhances insulin levels, increases glucose-stimulated insulin secretion, improves peripheral 
insulin sensitivity and prevents high-fat diets from inducing obesity [112]. Similarly, ghrelin 
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receptor antagonists which inhibit ghrelin signaling have been shown to improve the 
diabetic condition by promoting glucose-dependent insulin secretion [113]. Ghrelin can also 
inhibit the activity of glucose-sensing neurons in the dorsal vagal complex of rats, indicating 
that ghrelin manipulates the sensitivity of glucose-sensing neurons [114, 115].  
The pathophysiological role of ghrelin in glucose homeostasis was strengthened by the fact 
that ghrelin may decline endogenous glucose production through suppression of insulin 
secretory capacity [116], while reinforcing insulin action on glucose disposal [112]. A recent 
study demonstrated that acylated ghrelin has a positive correlation with insulin resistance, 
as indicated by the increased insulin and glucose concentrations, whereas correlation 
between des-acylated ghrelin and HOMA-IR was shown to be negative [117]. On the other 
hand, it has been reported that fasting ghrelin levels at any other point might be impossible 
to use for predicting the development of impaired glucose regulation [118]. The reduction of 
ghrelin levels were shown to be associated independently with T2DM, agreeing with the 
results of studies demonstrating that ghrelin has an inverse correlation with insulin 
resistance evaluated by HOMA-IR [119]. Moreover, increases in ghrelin during chronic 
alcohol use suggested that a role of ghrelin may contribute significantly to the overall 
alcohol response. It has likewise been reported that ghrelin is not only a regulator of glucose 
and insulin metabolism in the central nervous system (CNS), but also a modulator of those 
in the periphery. In the periphery, ghrelin has been shown to stimulate hepatic glucose 
production [120] and inhibit insulin release from pancreatic islets [121, 122]. Peripheral 
ghrelin produced in the gastrointestinal tract [103, 123] reaches ghrelin-receptors in the 
anterior pituitary and potentially in the mediobasal and mediolateral hypothalamus 
through the general circulation to stimulate GH release and to regulate energy homeostasis 
[124]. Therefore, it can be postulated that decreases in ghrelin concentrations as well as 
facilitation of the development of perturbations in glucose metabolism resulting from 
deregulation of the CNS and the periphery might lead to perseverance of T2DM. Besides, 
low blood ghrelin concentrations appears to influence growth hormone/insulin like growth 
facor-1-axis which may, in turn, affect increased insulin resistance and ultimately manifest 
T2DM [125].  
6. Leptin in glucose and insulin homeostasis 
Leptin, an adipocyte-derived anorexic peptide plays a primary role in regulation of energy 
homeostasis including food intake and energy expenditure involved in obesity, regulating 
overall metabolism and particularly glucose metabolism. Leptin is transported across the 
blood brain barrier (BBB) by binding to its receptor in the arcuate nucleus of the 
hypothalamus to regulate glucose metabolism via central leptin signaling, which modulates 
sympathetic and neuroendocrine activities [126, 127], as well as though peripheral signaling 
in insulin-sensitive tissues such as liver and muscle [128, 129]. A previous study 
demonstrated that serum leptin was positively correlated with fasting blood glucose in 
obese patients with DM, suggesting that resistance to insulin and leptin may have 
participated in increasing food intake in T2DM. Additionally, leptin has to be considered as 
a possible regulator of the gastrohypothalamic axis involved in short-term feeding 
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regulation [130] and may have a central role in islet cell growth and insulin secretion [131]. 
In addition, several other appetite-related hormones such as anorexigenic neuropeptides, 
alpha-melanocyte-stimulating hormone (alpha-MSH), proopiomelanocortin (POMC), 
cocaine and amphetamine regulated transcript (CART) and corticotropin-releasing hormone 
(CRH) are stimulated by leptin. Conversely, orexigenic neuropeptides NPY, melanin-
concentrating hormone (MCH), orexins and agouti-related peptide (AgRP) are inhibited by 
leptin which suppresses food intake and enhances energy expenditure through these central 
interactions, which is associated with T2DM [132-135].  
In the brain, obesity and T2DM typified by both insulin and leptin resistance, on account of 
either reduced BBB transport or impaired neuronal capacity to sense peripheral signals, 
causes increased concentrations of anorexigenic neuropeptides and reduced concentrations 
of orexigenic ones [136]. It has been postulated that leptin resistance might be due to 
defective leptin transport across the BBB [137]. Leptin enters the brain by a satiable transport 
system and that capacity of leptin transport is lower in obese individuals, thereby providing 
a mechanism for leptin resistance [138]. The development leptin resistance most likely 
involves a period of excess caloric intake, resulting in a disturbance of the leptin system, 
leading to sustained defects. The hypothalamus exposed to high leptin levels becomes less 
sensitive to leptin, resulting in a sustained increase in leptin levels [139]. Leptin resistance 
may also have functional implications in peripheral tissues expressing leptin receptors, such 
as pancreatic β cells, where insulin is synthesized and secreted; leptin may also affect 
hepatocytes, muscle and adipose tissue, where insulin exerts its function [140]. In all these 
tissues, an effect of leptin has been demonstrated on insulin secretion and on insulin-
induced activities such as glucose utilization [83, 141]. Also, increased leptin levels, probably 
reflecting leptin resistance, was shown to be strongly related to insulin resistance [142]. 
Moreover, peripheral leptin inhibits insulin secretion in pancreatic β-cells [83], whereas 
insulin stimulates leptin production in adipocytes [85]. Therefore, reciprocal interaction of 
leptin and insulin called ‘adipo-insular axis’ is central under physiological conditions.  
However, in few studies, glucose and insulin levels were able to increase circulating leptin 
levels, indicating that the capacity of leptin to suppress insulin secretion in pancreatic β-cell 
might be a possible involvement of T2DM [143, 144]. Interestingly, reduced leptin sensitivity 
of the pancreatic β-cell occurs concurrently with hyperinsulinemia resulting from not only 
decreased insulin sensitivity, but also increased insulin secretion, and consequently 
hyperleptimia as part of a vicious cycle that promotes both and insulin resistance [145]). 
Leptin has been shown to increase whole-body glucose utilization, decrease glycogen stores 
and inhibit insulin-stimulated glucose uptake [146], implying that increased leptin levels 
contribute to increased glycemia and altered glucose homeostasis [147]. Therefore, the 
capacity of leptin to suppress insulin secretion in pancreatic β-cell suggests a possible 
involvement in T2DM. Moreover, obese (ob) gene depleted mice exhibited susceptibility to 
the development of obesity and diabetic disorders, indicating that leptin-(an ob gene 
product) induced insulin resistance may be considered a major influence in developing 
T2DM [148]. Thus, animal models that are used to elucidate mechanisms underlying obesity 
and T2DM often display an altered diabetogenic imbalance, involving leptin. This suggests 
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that dysfunction of leptin’s ability in T2DM may not only represent a consequence of the 
disease, but also plays an important role in its cause.  
7. Inverse interactions between leptin and ghrelin  
Leptin is important for the negative feedback regulation of ghrelin in states of moderate 
body weight increase, whereas recombinant leptin administration is ineffective on altering 
ghrelin levels in healthy subjects [149]. There is currently evidence that ghrelin and leptin 
exert antagonistic effects via their specific receptors in the CNS and in peripheral tissues. 
Ghrelin increases appetite and food intake via centrally mediating actions but, peripherally 
it modulates pancreatic β-cells function as well as glucose and lipid metabolism [150]. The 
satiety inducing effects of leptin include the suppression of ghrelin secretion to induce 
anorexic effects [97]. Adipogenic as well as orexigenic effects of ghrelin are also most likely 
mediated by a specific central network of neurons that is also mediated by leptin [124, 151-
153].  
In the brain, ghrelin may transfort the BBB and bind to its receptors in the hypothalamus 
after secretion into the bloodstream from the stomach [105, 154, 155]. Ghrelin reaches the 
brain via the vagal nerve and nucleus tractus solitarus [154, 156] and is released locally in 
the hypothalamus, where it may directly affect various hypothalamic nuclei [154, 157]. In 
addition, central ghrelin may affect the energy centre in the hypothalamus and both ghrelin 
and leptin stimulate and suppress, respectively hypothalamic neurons containing various 
neuropeptides, resulting in anorexic or orexic effects on energy balance. Ghrelin thus 
stimulates the activity of neurons expressing NPY, AgRP and orexin [158-160] and inhibits 
POMC neurons and CRH-producing neurons [157]. The interaction between ghrelin and 
leptin in the hypothalamus indicates that these peptides have different effects in the 
hypothalamic neurons producing various orexigenic and anorexigenic peptides, presenting 
more or less opposing effects on energy balance.  
In hepatocytes, ghrelin reduces and leptin augments insulin signal transduction, resulting in 
increased and decreased glucose production, respectively [120]. In pancreatic β-cells, insulin 
release was stimulated by ghrelin but inhibited by leptin administration [3]. Insulin was 
postulated to act indirectly via ghrelin and leptin to suppress appetite [5]. However, 
attenuated suppressive action of insulin on ghrelin and particular association between 
insulin resistance and leptin resistance were shown in T2DM [5, 142]. Thus, leptin seems to 
the major determinant of ghrelin effects on progression of metabolic syndromes. 
8. Conclusion  
The studies discussed here demonstrate that the role of appetite regulating peptides, ghrelin 
and leptin, in alcohol patients with T2DM may be of high importance for clinical research 
and practice. The extensive functional interactions between these peptides, which may 
contribute significantly to the overall defecting glucose tolerance with regard to alcoholism, 
may have a new insight into mechanism of T2DM. Therefore, understanding of mechanisms 
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underlying the pivotal relations between ghrelin, leptin and glucose homeostasis during 
chronic use of alcohol represents an additional therapeutic intervention for T2DM. 
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